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Abstract
Background: Age-related macular degeneration (AMD) is a degenerative disorder of the central retina and the
foremost cause of blindness. The retinal pigment epithelium (RPE) is a primary site of disease pathogenesis. The
genetic basis of AMD is relatively well understood; however, this knowledge is yet to yield a treatment for the most
prevalent non-neovascular disease forms. Therefore, tissue-specific epigenetic mechanisms of gene regulation are of
considerable interest in AMD. We aimed to identify differentially methylated genes associated with AMD in the RPE
and differentiate local DNA methylation aberrations from global DNA methylation changes, as local DNA methylation
changes may be more amenable to therapeutic manipulation.
Methods: Epigenome-wide association study and targeted gene expression profiling were carried out in RPE cells from
eyes of human donors. We performed genome-wide DNA methylation profiling (Illumina 450k BeadChip array) on RPE
cells from 44 human donor eyes (25 AMD and 19 normal controls). We validated the findings using bisulfite
pyrosequencing in 55 RPE samples (30 AMD and 25 normal controls) including technical (n = 38) and independent
replicate samples (n = 17). Long interspersed nucleotide element 1 (LINE-1) analysis was then applied to assess global
DNA methylation changes in the RPE. RT-qPCR on independent donor RPE samples was performed to assess
gene expression changes.
Results: Genome-wide DNA methylation profiling identified differential methylation of multiple loci including the SKI
proto-oncogene (SKI) (p = 1.18 × 10−9), general transcription factor IIH subunit H4 (GTF2H4) (p = 7.03 × 10−7), and
Tenascin X (TNXB) (p = 6.30 × 10−6) genes in AMD. Bisulfite pyrosequencing validated the differentially methylated locus
cg18934822 in SKI, and cg22508626 within GTF2H4, and excluded global DNA methylation changes in the RPE in AMD.
We further demonstrated the differential expression of SKI, GTF2H4, and TNXB in the RPE of independent AMD donors.
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Conclusions: We report the largest genome-wide methylation analysis of RPE in AMD along with associated gene
expression changes to date, for the first-time reaching genome-wide significance, and identified novel targets for
functional and future therapeutic intervention studies. The novel differentially methylated genes SKI and GTF2H4 have
not been previously associated with AMD, and regulate disease pathways implicated in AMD, including TGF beta
signaling (SKI) and transcription-dependent DNA repair mechanisms (GTF2H4).
Background
Age-related macular degeneration (AMD) is a degenera-
tive disorder of the central retina and the most common
cause of sight impairment in those aged over 50 [1]. It is
predicted to affect 288 million people by 2040 [2]. AMD
progresses from early and intermediate forms through to
late AMD, which manifests as choroidal neovasculariza-
tion (CNV) and/or geographic atrophy (GA). Whilst
CNV (“wet” AMD) is treatable, currently, there is no
treatment for non-neovascular AMD forms. Early and
intermediate AMD are characterized by the accumula-
tion of medium size (between 63 and 125 μm) extracellu-
lar lipo-proteinaceous deposits termed drusen, located
between the inner collagenous layers of Bruch’s mem-
brane and the basement membrane of the retinal pig-
ment epithelium (RPE), pigmentary abnormalities, and
progressive photoreceptor dysfunction at the macula [3].
The genetics of AMD has been investigated extensively
and clinical trials based on genome-wide association
study (GWAS) candidate genes have emerged [4–6];
however, despite the success of genetic studies, causal
and functional effects of AMD risk variants are not
understood. Recently a clinical trial targeting the com-
plement pathway failed to meet the primary study end-
point (https://clinicaltrials.gov/ct2/show/NCT02247531).
Environmental risk factors associated with oxidative
stress have been identified, including smoking, dietary
fat, omega-3 fatty acid, and antioxidant intake, although
it is unclear how these factors contribute to the mecha-
nisms of disease in AMD [1].
Epigenetic dysfunction of the RPE, a primary site of
AMD pathogenesis, has been suggested to drive early
disease following the finding of a widespread decrease of
chromatin accessibility in AMD [7]. Tissue-specific
DNA methylation may underlie the poorly understood
interplay of genetic and environmental risk factors [8]
and several groups reported that DNA methylation
changes in individual genes may be associated with
AMD [9–13]. However, in these studies, candidate loci
did not reach genome-wide significance, and they were
hampered by small sample sizes of relevant tissues and
the use of peripheral blood as a proxy.
In this study, we investigated DNA methylation
changes in AMD by performing genome-wide DNA
methylation profiling in RPE cells of human donors (44
samples; 25 AMD and 19 normal) to investigate whether
DNA methylation underlies differential gene expression
in AMD.
Methods
Sample collection, grading, and DNA extraction
Ocular tissue for DNA methylation analyses (Illumina
450k BeadChip array and pyrosequencing) was obtained
from the Manchester Eye Bank, UK. DNA was extracted
between 24 and 36 h post-mortem from individuals aged
over 50 years. Demographic information obtained in-
cluded sex, age, cause and time of death, time of enucle-
ation, ocular history where possible (from General
Practitioner NHS summary sheets enclosed with the eye
donation consent forms), and any major medical condi-
tions. Eye dissection was performed under a GT Vision
GXM XTL3TV6 stereomicroscope fitted with a
GXCAM 5 digital color camera used to take
high-resolution macular photographs. Photographs for
grading were reviewed by one (LFP) and where uncer-
tainty was present two ophthalmologists (LFP and PB).
RPE cells were isolated from Bruch’s mechanically, by
scraping with a 22-gauge needle and removal with a sili-
cone brush. DNA was isolated from harvested RPE cells
using a DNA purification kit and bisulfite conversion
was performed using the Zymo EZ DNA methylation
tissue kit (Zymo Research, Irvine, USA). Tissue pheno-
typing was linked to the Age-Related Eye Disease Study
(AREDS) classification, using key features as described
in the Minnesota Grading System [14, 15] (MGS). We
subdivided the tissue into no AMD (no drusen or a few
small drusen < 63 μm) and AMD, based upon the cri-
teria for intermediate drusen (> 63 μm and < 125 μm), or
the presence of one or more large drusen (> 125 μm),
and the presence of pigmentary changes or geographic
atrophy (Additional file 1: Table S1 and S2). We deliber-
ately excluded samples with CNV (MGS level 4) for the
purposes of this study. The purity of RPE cells for
methylation studies was confirmed by measuring RPE,
retinal, neuronal, and choroidal markers in our in-house
RNA sequencing data. Analysis of DNA degradation
levels prior to methylation analyses was performed by
gel-electrophoresis in the manner described by Rhein et
al., (2015) [16].
The RPE samples used for expression studies (qRT-PCR
and RNA sequencing) were obtained by Lions Eye Insti-
tute of Transplant and Research (LEITR), Florida, USA
Porter et al. Clinical Epigenetics            (2019) 11:6 Page 2 of 14
[17]. After necessary pictures were obtained for grading,
the RPE tissues were brushed off, collected, and
stored in RNA later solution within a post-mortem
time of 6 h. Normal or AMD status was assigned by
MGS [14, 15] by an ophthalmologist (TWO)
(Additional file 1: Table S1 and S2).
Illumina Infinium Human Methylation 450k BeadChip
Array
DNA methylation levels were measured using the Illu-
mina Infinium HumanMethylation450 BeadChip Array
platform (Illumina, Inc., San Diego, CA, USA) that inter-
rogates over 450,000 CpG sites representing about 99%
of the RefSeq genes. Four microliters of bisulfite con-
verted DNA was processed and hybridized to the micro-
array according to the manufacturer’s protocol. Analysis
was performed at GenomeScan (GenomeScan B.V., Lei-
den, the Netherlands). All samples were run within a
single array with technical controls incorporated into
the experimental design and a duplicate sample run.
Data has been deposited in ArrayExpress with submis-
sion number E-MTAB-7183.
Quality control was conducted in GenomeStudio soft-
ware according to the manufacturer’s instructions,
assessed using the R script MethylAid with no initial
normalization. Data analysis was performed in R (version
3.3.1) integrating “minfi” [18], “DMRcate” [19], “limma”
[20], “missMethyl” [21], and “IlluminaHumanMethyla-
tion450kanno.ilmn12.hg1” using the M metric raw methy-
lation values. Data were further inspected for quality
metrics, adjusted for color channel imbalance, and
quantile-normalized using SWANN normalization. In the
DML analysis, the sample’s sex origin was predicted using
the R function “getSex.” Data sets were filtered to remove
probes from chromosomes X and Y, probes known to be
cross-reactive https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC3592906/ (supplementary material), and probes on
which poor quality data were generated (detection p
values ≥ 0.01). We removed probes associated with SNPs
of minor allele frequency (MAF) ≥ 0.05 using the function
“dropLociWithSnps.” A linear model-based DML analysis
was applied using the M values of filtered data and seven
parameters listed in Additional file 1: Table S3. Log2 FC
(odds ratio of the fold change) of M values for each con-
trast were computed and tested using t tests for associated
p values. p values were adjusted for multiple testing using
the FDR approach [22]. Significantly differential expres-
sion was defined as those with an FDR-adjusted p value <
10%. If no DML were detected or the number of DML
was less than 10, a p value cutoff of p ≤ 0.0001 was used.
Multidimensional scaling (MDS) plots, correlation heat-
maps, and PCA (principal component analysis) plots were
employed to visualize the data variation.
Differentially methylated region (DMR) analysis was
performed using DMRcate from the R package
DMPcate. A list of top CpGs was generated based on a
relaxed threshold p value ≤ 0.0001. The process was car-
ried out on AMD vs normal and interaction model pa-
rameters only.
We also applied the “GapHunter” algorithm in R to
our 450k array dataset to “flag” probes that displayed β
value distributions containing discrete clusters [23, 24].
Bisulfite pyrosequencing of candidate differentially
methylated positions
Bisulfite-pyrosequencing is an established technique in
single-nucleotide resolution, quantitative methylation
analysis of genomic regions [25]. Assays were designed
using PyroMark Assay Design Software (Version 2.0.1)
to interrogate regions containing or surrounding (< 100
bp upstream/downstream) candidate DML identified in
our Illumina Human Methylation 450k BeadChip. The
percent methylation for each CpG site within the target
sequence was calculated using the PyroQCpG Software
(Qiagen) with non-CpG cytosine residues used as
built-in controls to verify complete bisulfite conversion.
Genomic DNA was bisulfite converted using the EZ
DNA Methylation-Gold Kit (Zymo Research, Irvine,
USA). Due to limited amounts of starting DNA, we
employed “Quantitative Methylation Analysis of Minute
DNA Amounts After Whole Bisulfitome Amplification”,
known as qMAMBA [26, 27]. DNA Whole Genome
Amplification (WGA) was carried out on bisulfite-modi-
fied RPE gDNA using the Repli-G Screening Kit (Qia-
gen, Hilden, Germany) as per the manufacturer’s
instructions. PCR amplicons were designed using Pyro-
Mark Assay Design SW 2.0 software (Qiagen, Hilden,
Germany) (Additional file 1: Table S4) with a methyla-
tion standard curve used ensure the assay was without
methylation bias [25]. Robust PCR end-products were
immobilized to suspended Streptavidin Sepharose™
High-Performance beads (GE Healthcare Life Sciences,
Pittsburgh, Pennsylvania, USA) and single-strand DNA
(ssDNA) template captured from candidate gene ampli-
cons [25]. Sequencing primers (10 pmol; Eurofins Gen-
omics, Edelberg, Germany) were subsequently annealed
to the ssDNA template and pyrosequenced using a
PyroMark-Q96 ID as per manufacturer’s instructions.
All pyrosequencing data were analyzed using CpG
run-analysis on PyroMark Q96 (version 2. 5. 8). Mean
methylation was calculated for ≥ 4 CpGs per genomic re-
gion with Mann-Whitney U test used to compare differ-
ences in mean-methylation between AMD and normal
patients. All statistical analysis was carried out using
GraphPad Prism (Version 7.0, GraphPad Software Inc.,
San Diego, CA, USA). Six samples belonging to the DNA
methylation array cohort (epigenome-wide association
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study (EWAS) cohort) were excluded from bisulfite-pyro-
sequencing due to limited DNA availability, DNA degrad-
ation, or poor-quality PCR-amplification. The final
cohort comprised 55 RPE patient and normal sam-
ples, with no significant age differences detected
(Additional file 1: Table S5). Pooled and sex-stratified
analyses were performed.
Quantitative real-time PCR (qRT-PCR) of differentially
methylated genes
Expression levels of candidate differentially methylated
genes identified from our array, GTF2H4, SKI, RIC3,
EIF2AK3, GRIA4, and DMR gene TNXB were determined
by qRT-PCR (delta delta Ct) using 7900HT Fast
Real-Time PCR (Thermofisher Scientific, MA, USA).
Total RNA was extracted from RPE isolated from four
AMD-affected donors (excluding CNV) and three normal
donors (Additional file 1: Table S2) from LEITR, Florida,
using Direct–Zol RNA MiniPrep kit (Zymo Research, CA,
USA). Two micrograms of total RNA was reverse tran-
scribed into cDNA using Superscript III First-Strand
cDNA Synthesis (cat no. 18080-051, Thermo Fisher Scien-
tific, MA, USA) and equal amounts of cDNA (30 ng) amp-
lified using Power Up SYBR Green with gene-specific
primers (Additional file 1: Table S6). GAPDH was in-
cluded as an endogenous control. Fold change was calcu-
lated between different subgroups using the delta delta Ct
method [28] and significantly differentially expressed
genes were identified based on a p value< 0.05. Experi-
ments were performed in triplicate and data pooled to
generate normal versus AMD expression changes.
Results
Differentially methylated loci identified in AMD using the
Illumina Infinium Human Methylation 450k BeadChip
array
We performed an EWAS using the Illumina Human
Methylation 450k BeadChip array (450k array) to inves-
tigate a role for DNA methylation in AMD using RPE
samples from AMD donors (n = 25) and normal control
donors (n = 19) from the Manchester Eye Bank
(Additional file 1: Table S2 and S5). All AMD samples
analyzed were early (level 2) and intermediate (level 3)
AMD, with level 2 samples representing 84% of the co-
hort analyzed and level 3 samples the remaining 16%.
AMD and normal control donors had comparable
demographic characteristics (Additional file 1: Table S5).
Data quality assessment based on probe signals com-
pared to background noise and quality control report
function [18] concluded acceptable data quality for in-
clusion in downstream analyses (Additional file 2: Figure
S1, S2, S3). MDS analysis indicated that sex was the
strongest discriminating factor.
We employed linear interaction modeling considering
sex-related methylation differences, batch effect, and dis-
ease state, comparing AMD to normal RPE samples. We
identified 11 differentially methylated loci (DML) with an
FDR < 20% (Table 1). We then applied a mean methylation
difference cutoff (Δβ) of 10% to the methylation dataset
(FDR ≤ 0.2, Δβ ≥ 0.1 (10% methylation difference)) identify-
ing 8 DML (Table 2). Of the 8 DML, 3 candidate CpG
probes, cg18486102 (FAIM2, p = 1.08 × 10−12), cg18934822
(SKI, p = 1.18 × 10−9), and cg23169512 (p = 2.08 × 10−8),
reached genome-wide significance (p ≤ 5 × 10−8).
Candidate DML were comprised of 4 promoter, 3
gene-body, and an intragenic-based CpG probe
(cg23169512, Chr15:60290666, hg19) that mapped 6.4 kb
upstream of FOXB1 transcriptional start site (TSS).
Identification of AMD differentially methylated CpG-rich
genomic regions, involving adjacent differentially
methylated loci close together
We performed DMR analysis as methylation events
regulating mRNA transcription in human disease are re-
ported to occur in CpG-rich genomic regions [29]. .As
no DMRs were detected using an FDR ≤ 0.1, a p value
cut off criterion (P ≤ 0.0001) was applied resulting in the
identification of four DMRs (Table 3). Furthermore, two
genome-wide significant DML, cg18486102 and
cg18934822, mapped to two DMR within FAIM2 and
SKI respectively (Table 3). The fourth DMR mapping to
TNXB (chr6:32063835-32064258, hg19) encodes the
protein Tenascin X (TNX) (Fig. 1).
To examine whether the DML and DMR identified
may overlap with AMD-associated genetic variants, we
systematically probed the DML and DMR for the pres-
ence of one or more AMD-associated single nucleotide
polymorphisms (SNP) [4]. Two variants near TNXB have
been associated with AMD (rs12153855 and rs9391734)
[30, 31] (Additional file 1: Table S7). SNP rs12153855 is
located in intron 1 of TNXB, 10969 bp downstream of
the DMR start point, and rs9391734 is 33,898 bp down-
stream of the DMR start point, respectively. rs429608
(associated with C2 and complement factor B [32] is
133,373 bp upstream from the DMR within TNXB.
rs3130783, associated with GTF2H4, is 105,549 bp up-
stream of the CpG site and has also been identified as
an AMD-associated disease locus [32]. These findings
potentially demonstrate some overlap between the ob-
served differences in the region-specific DNA methyla-
tion in TNXB and the TNXB AMD-associated genetic
variants (Additional file 1: Table S7).
Evaluating sex differences does not detect any sex-
specific differentially methylated loci in AMD
Several studies revealed that women have a higher risk
of developing AMD than men [33–35]. We analyzed the
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locus by locus interaction of DNA methylation levels be-
tween males (n = 27) and females (n = 17) in AMD and
normal control RPE cells, to identify sex-specific
differentially methylated loci using a value of FDR ≤ 0.1.
We did not identify variants with a genome-wide signifi-
cant sex-dependent association with AMD (Psexdiff ≤ 5 ×
10−8) in our systematic genome-wide search (data not
shown), thereby demonstrating that there are no sexually
dimorphic differentially methylated DNA loci in our
dataset.
Bisulfite pyrosequencing validates DML cg18934822 in an
intronic region of SKI and cg22508626 in the gene body
of GTF2H4
We then interrogated cg18934822 (SKI), cg22508626
(GTF2H4), cg26347887 (EIF2AK3), cg01560972 (RIC3),
cg18486102 (FAIM2), and cg03243226 (GRIA4) in tech-
nical (n = 38) and biological (n = 17) validation sets from
human RPE samples to quantify mean methylation
differences between AMD and normal RPE cells (Add-
itional file 1: Table S2 and S5). Targets were selected
based on feasibility of pyrosequencing assay design,
ontological relevance, transcriptomic evidence [17, 32,
36] (Additional file 1: Table S7), and FDR < 0.2, Δβ ± 0.1
and p ≤ 10−6. Combined cohort (n = 55) included 26
AMD level 2 samples (81.25%) and 6 AMD level 3 sam-
ples (18.75%). We confirmed reduced methylation for
cg18934822 (SKI) in AMD compared to normal control
donor samples (Mann-Whitney U test, p = 0.0309), in
agreement with the 450k array data (Fig. 2). We also
confirmed the increased methylation observed in our
450k array data for cg22508626 (GTF2H4, Fig. 3). This
probe reached significance in sex-stratified analysis with
significant hypermethylation observed in AMD in fe-
males (Mann-Whitney U test, p = 0.0292) (Fig. 3f ).
Bisulfite-pyrosequencing analysis of the promoter-based
targets cg01560972 (RIC3), cg18486102 (FAIM2),
cg03243226 (GRIA4), and cg26347887 (EIF2AK3) showed
Table 1 Significantly differentially methylated CpG probes identified in AMD RPE cells
Probe ID Log2 FC Adjusted
p value
False discovery
rate (< 0.2)
Δβ (* > 10%) Chromosome Position Relation to
CpG island
UCSC gene
name
Relation to gene
cg18486102 1.81 1.08E−12 4.6E−07 *0.20 chr12 50297777 Island FAIM2 TSS200
cg18934822 − 3.00 1.18E−09 2.5E−04 *− 0.11 chr1 2191402 Open Sea SKI Body
cg23169512 − 3.51 2.08E−08 2.9E−03 *− 0.33 chr15 60290666 N_Shore
cg22508626 1.02 7.03E−07 6.0E−02 *0.12 chr6 30879905 N_Shore GTF2H4 Body
cg01560972 − 3.87 2.03E−06 1.4E−01 *− 0.33 chr11 8190837 S_Shore RIC3 TSS1500
cg26962595 1.18 2.75E−06 1.6E−01 0.02 chr11 72504889 Island STARD10 TSS200
cg11897517 1.67 3.87E−06 1.6E−01 0.02 chr6 109761938 Island SMPD2 5′UTR
cg04838987 − 1.76 3.98E−06 1.6E−01 *− 0.18 chr20 33734406 N_Shore EDEM2 Body
cg11241206 − 2.82 4.44E−06 1.6E−01 *− 0.35 chr11 27723128 S_Shore BDNF TSS1500; 5′UTR
cg03611060 2.51 5.00E−06 1.6E−01 *− 0.14 chr1 59281067 Island
cg26347887 − 2.87 5.16E−06 1.6E−01 *− 0.28 chr2 88927196 Island EIF2AK3 TSS200
Δβ mean β value AMD—mean β value control, TSS transcription start site, 5′UTR 5′-untranslated region, 3′-UTR 3′-untranslated region, Body gene body, Intragenic
intragenic region
Analysis of Illumina 450k BeadChip array data using linear interaction modeling considering independent variables (sex M/F and batch effect) and their interaction
with DNA methylation. Significantly differentially methylated CpG probes in contrasts AMD/normal with a FDR of < 20% are shown. cg23169512 is approximately
10 kb from FOXB1, and cg03611061 is within the long intergenic non-protein coding RNA 1135 and 30 kb upstream of JUN proto-oncogene
Table 2 Significantly differentially methylated CpG probes in AMD RPE cells with FDR < 20% also showing a mean methylation
difference between AMD and normal RPE cells of 10% minimum (FDR < 0.2, Δβ ≥ 0.1 (10%))
Probe ID Gene Adjusted p value Δβ Chromosome CpG position Accession reference Probe location
cg18486102 FAIM2 1.08E−12 0.20 12 50297777 NM_012306 TSS200
cg18934822 SKI 1.18E−09 0.11 1 2191402 NM_003036 Body
cg23169512 2.08E−08 0.33 15 60290666 Intragenic
cg22508626 GTF2H4 7.03E−07 0.11 6 30879905 NM_001517 Body
cg01560972 RIC3 2.03E−06 0.33 11 8190837 NM_024557 TSS1500
cg04838987 EDEM2 3.98E−06 0.18 20 33734406 NM_001145025 Body
cg11241206 BDNF 4.44E−06 0.30 11 27723128 NM_001143813 TSS1500
cg26347887 EIF2AK3 5.16E−06 0.28 2 88927196 NM_004836 TSS200
TSS transcription start site, 5′UTR 5′-untranslated region, 3′-UTR 3′-untranslated region, Body gene body, Intragenic intragenic region
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inconsistent methylation differences compared with the
direction of methylation change in the DNA methylation
array (Fig. 4). Pyrosequencing of cg01560972 within the
promoter of RIC3 showed increased mean methylation
observed in AMD female samples, reaching statistical sig-
nificance (p = 0.0327) (Fig. 4c). cg18486102 within the
promoter region of FAIM2 showed significantly reduced
methylation in males (p = 0.0276) (Fig. 4e). cg03243226,
within the promoter of GRIA4, demonstrated a significant
reduction in methylation in females p = 0.0279) (Fig. 4l).
Bisulfite-pyrosequencing analysis of the promoter-based
cg26347887 (EIF2AK3) displayed extremely low levels of
methylation in the majority of tested samples (≤ 2%
methylation) (Fig. 4g–i).
cg26347887 (EIF2AK3), cg1560972 (RIC3), and
cg18486102 (FAIM2) were “flagged” by the GapHunter
algorithm because they displayed clustered signals that
may reflect a genotype-related methylation state [23]
(Additional file 2: Figure S4), rendering validation by
reproduction of direction of methylation change prob-
lematic at these loci (Additional file 2: Figure S5). Clus-
tered β value distributions were evident in 74,355
probes in the 450k array data, highlighting that SNPs
not routinely excluded from analyses may exert a large
Table 3 Differentially methylated regions identified in AMD RPE cells using a relaxed p value cutoff criterion (p ≤ 0.0001)
Gene CpG number Chromosome coordinates Minimum FDR DMR Length (bp) DMR location
FAIM2 7 chr12:50297477-50297945 8.39E−16 469 Promoter/exon 1/intron 1
SKI 6 chr1:2190850-2191658 2.92E−08 809 Intron 1
3 chr17:14201680-14201938 3.60E−07 259 Intragenic
TNXB 15 chr6:32063835-32064258 6.30E−06 424 Exon 3
Fig. 1 Differentially methylated region identified within tenascin X (TNXB). Upper panel: schematic representation of differentially methylated
region (DMR) identified in the Illumina 450k BeadChip array spanning 424 bp containing 15 CpG probes within exon 3 of TNXB. Lower panel:
univariate analyses of β values of seven CpG probes within the differentially methylated region. a–g Significant decrease in methylation is shown
at seven CpG probes within the DMR in TNXB (cg01337207, p = 0.0204; cg26266427, p = 0.0361; cg10365886, p = 0.0248; cg07524919, p = 0.0065;
cg00872984, p = 0.0088; cg27387193, p = 0.0191; cg17662683, p = 0.0233) (*p≤ 0.05, **p≤ 0.01). Mann-Whitney U test was used for statistical
analyses between all groups tested
Porter et al. Clinical Epigenetics            (2019) 11:6 Page 6 of 14
effect on methylation states (Additional file 2: Figure
S4, Additional file 1: Table S8).
Site and region-specific DNA methylation differences
observed in AMD are not due to global DNA methylation
changes
A recent study assessing global chromatin accessibility
in AMD using Assay for Transposase-Accessible Chro-
matin using sequencing (ATAC-seq) reported that global
reduction of chromatin accessibility occurs in the RPE
with early disease [7]. Global DNA-methylation changes
have also been identified as a prominent feature of
age-related diseases in humans and are associated with
genomic instability [26]. Therefore, we analyzed global
DNA methylation in RPE samples from AMD donors
and normal controls (n = 55) (Additional file 1: Table S5)
employing the established long interspersed nucleotide
element 1 (LINE-1) as a proxy element [26]. No significant
mean methylation difference was observed in AMD com-
pared to normal human donor samples (Fig. 5). These
data imply that site and region-specific DNA methylation
differences observed in early and intermediate AMD are
not due to global DNA methylation changes.
Gene expression changes are present in differentially
methylated genes SKI, GTF2H4, and DMR gene TNXB in
AMD
To prioritize candidate genes for gene expression studies,
we investigated individual differentially methylated genes
by mining the literature, open access RNA sequencing
data, and performed a systematic search for any associ-
ation with AMD genetic variants (Additional file 1: Table
S7). We also performed a systematic search of our differ-
entially methylated CpG loci (Table 2) and DMR (Table 3)
Fig. 2 Bisulfite pyrosequencing of candidate gene SKI (cg18934822) validates direction of methylation change identified in 450k array. a–c Univariate
analysis of SKI (cg18934822) in Illumina 450k BeadChip array. a Methylation β values for AMD (n = 25) compared to normal (n = 19) donor RPE cells
after normalization, in addition to analysis of sex-stratified results for cg18934822 (SKI). Significantly reduced methylation levels are observed in AMD
(p < 0.0001), as well as in both AMD male (n = 15) (b) and AMD female (n = 10) (c) compared to normal male (n = 12) (p = 0.0063) and normal female
(n = 7) (p = 0.0031) human RPE donor cells respectively. d–f Bisulfite pyrosequencing of candidate gene SKI (cg18934822) in combined technical and
independent sample replications. d Reduced methylation of cg18934822 (SKI) is identified in AMD (n = 30) compared to normal donor RPE cells
(n = 25) (p = 0.0309). e Reduced methylation of cg18934822 (SKI) is identified in AMD AMD male (n = 20) compared to normal male (n = 18)
(p = 0.1223) and f AMD female (n = 10) compared to normal female donor samples (n = 7) (p = 0.1002). (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001;
****p ≤ 0.0001). All statistical analysis was performed using the Mann-Whitney U test
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for enrichment of histone modifications indicative of gene
regulatory functions including H3K4me1 (enhancer signa-
ture), H3K27ac (transcription activation enhancer),
H3K4me3 (promoter signature), and CTCF (insulator re-
gion) using the ENCODE data for different cells and cell
lines (www.encodeproject.org, accessed 1 March 2018)
(Additional file 1: Table S9 and S10). We noted an enrich-
ment for histone modifications associated with gene regula-
tory activities at a number of differentially methylated CpG
loci and in all DMR in AMD (Additional file 1: Table S9
and S10). Of particular note, both the individual CpG locus
and the region surrounding cg18934822 (SKI) was
enriched for the enhancer signature H3K4me1 (Add-
itional file 2: Figure S6). A more targeted search for
genomic regulatory elements in RPE was then per-
formed, using the open access data from Cherry et al.
(doi: https://doi.org/10.1101/412361, http://biorxiv.org/
cgi/content/short/412361v1, Epigenomic Profiling and
Single-Nucleus-RNA-Seq Reveal Cis-Regulatory Ele-
ments in Human Retina, Macula and RPE and
Non-Coding Genetic Variation), accessed 14 September
2018 (Additional file 1: Table S11). The differentially
methylated CpG probe cg26347887 within EIF2AK3
was found to be within a putative cis-regulatory elem-
ent (CRE) in RPE/choroid tissue (Additional file 1:
Table S11). Finally, we analyzed the ATAC-sequencing
peaks identified in RPE by Wang et al. [7] because
ATAC-sequencing identifies accessible DNA regions as-
sociated with increased gene activity. Differentially
methylated CpG probes in AMD cg26347887
(EIF2AK3), cg18486102 (FAIM2), cg01560972 (RIC3),
cg26962595 (STARD10), cg11897517 (SMPD2), and
Fig. 3 Bisulfite pyrosequencing of candidate gene GTF2H4 (cg22508626) validates direction of methylation change identified in 450k array. a–c
Univariate analysis of GTF2H4 cg22508626 in Illumina 450k BeadChip array. a Methylation β values for AMD (n = 25) compared to normal RPE
donor cells (n = 19) after normalization, in addition to analysis of sex-stratified results for cg22508626 (GTF2H4). Significantly increased methylation
levels are observed in AMD compared to normal (p = 0.0003), in addition to both b AMD male (n = 15) and c AMD female (n = 10) compared to
normal male (n = 12) (p = 0.0074) and normal female (n = 7) (p = 0.0136) human donor samples respectively. d–f Bisulfite pyrosequencing of candidate
gene GTF2H4 (cg22508626) in combined technical and independent sample replications. d Mean methylation difference observed in cg22508626
(GTF2H4) in AMD (n = 29) compared to normal donor samples (n = 24) does not reach statistical significance (p = 0.1263). Sex-stratified analysis reveals
no significant methylation differences in e AMD male (n = 18) versus normal male (n = 18) donor samples. Significantly increased methylation is
observed in f AMD female (n = 11) versus normal male (n = 6) (p = 0.0292). (*p≤ 0.05)(**p≤ 0.01)(***p≤ 0.001)(****p≤ 0.0001). All statistical analysis was
performed using the Mann-Whitney U test
Porter et al. Clinical Epigenetics            (2019) 11:6 Page 8 of 14
cg04838987 (EDEM2) were associated with ATAC
sequencing peaks in the RPE (Additional file 1: Table
S12).
We performed RT-qPCR on independent human RPE
donor samples from LEITR, Florida, with AMD and nor-
mal controls for the most promising target genes includ-
ing SKI, GTF2H4, TNXB, RIC3, and EIF2AK3. GRIA4
was selected because differential GRIA4 expression has
been reported in AMD [37] (Additional file 1: Table S7).
Expression of SKI, GTF2H4, EIF2AK3, and TNXB was
significantly reduced in level 2 AMD compared to nor-
mal human donor RPE samples (Fig. 6). Of note, signifi-
cant expression changes were also present EIF2AK3
and GTF2H4 in level 3 AMD RPE cells. No mRNA
expression changes were noted for RIC3, and GRIA4
expression levels were very low in AMD (data not
shown). Further analysis of our RNA sequencing data
[17] confirmed significant decrease in the relative
Fig. 4 Bisulfite pyrosequencing of candidate genes: RIC3 (cg01560972), FAIM2 (cg18486102), EIF2AK3 (cg26347887), and GRIA4 (cg03243226). a No
significant mean methylation difference was observed for cg01560972 (RIC3) in AMD (n = 30) compared to normal (n = 25) donor RPE cells
(p = 0.9491). b Sex-stratified analysis did not reveal significant differences in AMD male (n = 18) compared to normal male (n = 18) (p = 0.2006). c A
significant hypermethylation was observed in AMD female (n = 12) compared to normal female (n = 7) human donor samples (p = 0.0327). d No
significant mean methylation difference was observed for cg18486102 (FAIM2) in AMD (n = 30) compared to normal donor RPE cells
(n = 25) (p = 0.1672). e Sex-stratified analysis revealed significant differential hypomethylation in males (AMD male n = 19, normal male,
n = 18) (p = 0.0276). No significant mean methylation difference was observed in AMD female (n = 11) compared to normal female (n = 7)
human donor RPE cells (p = 0.4362). f No significant methylation difference was observed in cg26347887 (EIF2AK3) in AMD (n = 28)
compared to human donor samples (n = 23) (p = 0.4546) g–i. Sex-stratified results did not reveal significant methylation changes in males
or females. j No significant mean methylation difference was observed for cg03243226 (GRIA4) in AMD (n = 30) compared to human
donor RPE cells (n = 25) (p = 0.2053). k Sex-stratified analysis did not show significant differential hypomethylation in AMD male (n = 18)
compared to normal male (n = 18) (p = 0.8197); however, a significant mean methylation difference was observed in AMD female (n = 12)
compared to normal female (n = 7) (p = 0.0279) human donor RPE samples (l). All statistical analysis was performed using the Mann-
Whitney U test (*p ≤ 0.05)
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Fig. 5 Global methylation analysis of LINE-1 using bisulfite pyrosequencing of AMD RPE cells compared to normals. Mean methylation of LINE-1
compared to normals using bisulfite pyrosequencing. a LINE-1 analysis did not identify significant differences between AMD donor RPE cells
(n = 29) and normal donor RPE cells (n = 23) (p = 0.8788). Sex-stratified analyses revealed no significant methylation differences in AMD male
(n = 17) compared to normal male (n = 18) (p = 0.7730) (b) or AMD female (n = 12) compared to normal female human RPE cells (n = 5) (p = 0.8361)
(c). All statistical analysis was performed using the Mann-Whitney U test
Fig. 6 Gene expression of SKI, GTF2H4, TNXB, and EIF2AK3 and in human donor RPE samples. Relative mRNA quantification of SKI (a), GTF2H4 (b),
TNXB (c), and EIF2AK3 (d) using RT-qPCR in AMD (n = 4) compared to normal (n = 3) human donor samples. Significant reduction in SKI (p = 0.0235) (a),
GTF2H4 (p = 0.0174) (b), TNXB (p = 0.05) (c), and EIF2AK3 (p = 0.011) (d) was present in AMD (*p≤ 0.05). All statistical analysis was performed using an
unpaired Student’s t test
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expression of SKI, GTF2H4, and TNXB transcripts in
RPE (n = 5) donor samples from AMD patients when
compared with controls (n = 7) (Additional file 2:
Figure S7, Additional file 1: Table S2).
Discussion
Here, we identify novel targets for functional and poten-
tial future therapeutic intervention studies, identifying
differentially methylated and expressed genes SKI,
GTF2H4, and TNXB that regulate disease pathways im-
plicated in AMD. Our findings highlight that DNA
methylation changes may influence differential gene ex-
pression in early/intermediate AMD. This is an import-
ant finding as aberrant DNA methylation in disease may
be altered therapeutically [38, 39]. A focus on the RPE is
deliberate as the clinical pattern of AMD progression
suggests that changes in the RPE precede the dysfunc-
tion and death of macular photoreceptors [40] and epi-
genetic dysfunction of the RPE may drive disease [7].
This is to date the largest DNA methylation study of
RPE in AMD with a sample size of relevant ocular tissue
significantly higher than those used in other epigenomic
studies of AMD (Wang et al., 2018 [7]: RPE—12 AMD,
8 normal; retina—14 AMD, 11 normal; Oliver et al. [12]:
retina—9 AMD, 9 normal; Oliver et al. [9]; RPE—3
AMD, 3 normal; retina—9 AMD, 6 normal; Hunter et al.
[10]: RPE—10 AMD, 11 normal) and identifying candi-
date DML that reach genome-wide significance.
SKI encodes the SKI proto-oncogene protein that
functions as a negative regulator of TGF-β signaling
through direct interaction with Smad1-4 [41]. TGF-β
signaling has been shown to play a role in RPE cell mi-
gration [42]and oxidative stress-induced RPE senescence
[43] and modulates complement over-activation, a
well-characterized phenomenon of early AMD [44]. Re-
duced SKI in the RPE in AMD could result in increased
TGF-β signaling in the RPE, as observed in independent
studies [45]. TGF-β stimulation decreases the expression
of membrane-bound complement inhibitors on human
airway epithelial cells [46] and modulates complement
C3 deposition in the RPE [44]. DNA methylation events
within SKI may contribute to complement dysfunction
in AMD, providing potential novel therapeutic ap-
proaches to modulate complement deposition in RPE in
AMD. Transcriptional changes in SKI in AMD RPE have
been shown in a previous small study using an Agilent
expression array [36] (Additional file 1: Table S7), pro-
viding evidence for a need to regulate TGF-β signaling
in AMD.
GTF2H4 is a core component of the highly conserved
transcription factor II H (TFIIH) basal transcription factor
involved in the initiation of transcription, transition from
initiation to elongation, and transcription-dependent nu-
cleotide excision repair (NER) of DNA [47]. We observed
increased methylation of cg22508626 in the gene body of
GTF2H4 and associated this finding with reduced expres-
sion of GTF2H4 in RPE in AMD. This observation sug-
gests a transcriptional role for exonic methylation, which
has been previously posited in alternative splicing regula-
tion [48]. Loss of function mutations in core complex
proteins of TFIIH are implicated in rare autosomal
recessive human diseases with cell-specific premature
aging phenotypes such as xeroderma pigmentosum (DNA
repair cancer syndrome), Cockayne syndrome (DNA re-
pair and transcription syndrome/segmental progeria/ret-
inal degeneration), and trichothiodystrophy (DNA repair
and transcription syndrome/age-associated pigmentary
retinopathy and photoreceptor degeneration) [47, 49]. Re-
duced TFIIB activity causes impaired tissue handling of
oxidative stress lesions that interfere with transcription
and the consequent stalled RNA polymerase forms a
major trigger for apoptosis [47]. Of relevance, rs3130783
associated with GTF2H4 has also been identified as an
AMD-associated disease locus [32] and several studies
have identified GTF2H4 transcriptional changes in
AMD RPE [10, 36]. Reduced expression of GTF2H4,
as a potential consequence of increased methylation
of GTF2H4 cg22508626, suggests that reduced
transcription-dependent DNA repair in the RPE may
play a role in AMD.
Our analysis also established the presence of four
DMR in AMD RPE (Table 3) including a DMR in TNXB
containing 15 consecutive CpG probes spanning 424 bp
in exon 3 with seven consecutive CpG probes displaying
a significant reduction in methylation within this region
(Fig. 1). TNX functions in extracellular matrix (ECM)
maturation and collagen fibrillogenesis [50], and TNXB
null mutations result in the connective tissue disorder
Ehlers-Danlos Syndrome [51]. We observed a significant
reduction in relative TNXB mRNA expression in early
AMD RPE (Fig. 6). TNX has been shown to localize
within the Bruch’s membrane/choroid complex and
displays differential expression in AMD patient plasma
compared to normal donor samples [52, 53]. Further-
more, multiple GWAS have identified an AMD risk
locus in the 6p21.3 region associated with TNXB
(Additional file 1: Table S7) [30–32] suggesting a role for
TNXB with altered ECM turnover in the pathogenesis of
AMD.
An important factor in our 450k data analysis was the
identification of sex as the strongest discriminating factor.
Linear interaction modeling was able to normalize for this
strong underlying sex-related methylation difference in
our bioinformatic analyses. Pyrosequencing analyses were
therefore sex-stratified to account for underlying gender-
related methylation differences present at some loci.
Sex-stratification however reduced the number of samples
in the analyses leading to a potential lack of power to
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detect differential methylation by pyrosequencing at some
loci. Therefore, identification of methylation changes in
one gender only likely represents under-powering of the
technique to detect small methylation changes.
The use of donor tissue with a post-mortem time
interval of 24–36 h for DNA methylation analyses is a
limitation of this study. However, we made significant at-
tempts to minimize DNA methylation variance linked to
postmortem time by extracting all our DNA within a 12
h interval, because DNA methylation variance increases
when using tissues with different postmortem collection
times, with particularly high variance shown for DNA
samples extracted after 72 h [16]. There is evidence to
suggest that postmortem times of 24–36 h should not
affect the validity of our DNA methylation results sig-
nificantly [16]. DNA methylation is a very stable modifi-
cation and epigenetic preservation of methylation
patterns has been shown in archeological subjects [54]
and in heterogeneous collections of human blood and
brain tissue samples [16, 55–57].
Conclusions
This is the largest genome-wide methylation study re-
ported to date using human RPE cells to show a rela-
tionship between differentially methylated loci and
regions and early/intermediate AMD. Our data also
demonstrates gene expression changes in differentially
methylated genes SKI, GTF2H4, and TNXB. Importantly,
identified genes SKI and GTF2H4 have not been previ-
ously linked to AMD. We also show that the differen-
tially methylated loci and regions identified are not due
to global DNA methylation changes. Differentially meth-
ylated genes identified in this study are implicated in dis-
ease pathways that overlap with known pathological
processes. Characterization and understanding of methy-
lation events in AMD may focus efforts on the most
relevant pathogenic mechanisms of AMD development.
Our findings provide new targets and a rational basis for
the design of much-needed therapeutic strategies.
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